More Stories

Informist, Friday, Aug. 14, 2026

 

MUMBAI – The Nifty Pharma index is expected to be range-bound next week, primarily because of a high likelihood of profit-taking. Shares of index constituents have risen sharply over the past six months on the back of strong domestic sales growth reported by the companies and defensive purchases by investors. This week, stocks of some contract development and manufacturing organisations continued to outperform their industry peers, but some others faced profit-taking at high levels. 

 

"Investors continue to punish companies that have a large presence in the US," an analyst at a domestic brokerage said. "Lupin's result shows that US-focussed companies continue to struggle with price erosion." However, the analyst added that new drug launches "look exciting" and the price erosion in sales of key generics such as Tolvaptan, Mirabegron, and, chiefly, Revlimid are forcing companies to diversify into different fields such as biosimilars, which will be beneficial for them in the long term.

 

While the war in West Asia has opened up a new stream of investors that sought exposure to pharmaceutical companies for their largely inelastic demand, many have "stayed for long", the analyst said. This buying in pharma stocks continued due to very strong traction in domestic sales, favourable commentary in rest-of-the-world markets, and an expected pick-up in US sales. Additionally, stocks of contract development manufacturers rose sharply on a healthy discretionary spending trend in the US and strong revenue growth in the June quarter.

 

For the past two weeks, the Nifty Pharma index has been consolidating in a narrow range of 26350–26800 points. The possibility of some profit-taking cannot be ruled out at this juncture, Vipin Kumar, assistant vice-president of research at Globe Capital Market, said. The overall chart structure remains positive as long as the index holds above the 25300–25400 points, the analyst said, and suggested that any dip toward 25600 points should be viewed as a fresh buying opportunity.

 

This week, the Nifty Pharma index ended nearly 0.4% lower at 26445.55 points. Shares of contract development manufacturers like Gland Pharma and Sai Life Sciences rose over 14% and 6%, respectively. Divi's Laboratories also closed the week over 2% higher. In the past 30 days, stocks of the three contract development manufacturers have risen over 14–19%. Meanwhile, shares of Wockhardt, Alkem Laboratories, Laurus Labs, and Biocon, all of which operate in this space, ended 2–4% lower. Wockhardt and Laurus Labs have risen over 4% and 14% in the past 30 days, respectively. Shares of Piramal Pharma have risen over 20% in the past 30 days, but ended the week 1.4% lower Friday.

 

TOP HEADLINES

* Earnings Review: Natco Pharma Q1 profit down 57% on sharp revenue decline
* Earnings Review: Alkem Lab Q1 PAT, sales slightly below view; expenses rise
* Analyst Concall: Max Health says medical colleges to fetch over 25% returns
* Gland Pharma appoints Deepak Sapra as CEO with effect from Nov 16
* Supriya Lifescience Apr-Jun PAT falls 31% YoY to INR 240.43 million
* HC upholds bar on Alder Biochem from using 'Biochem' on Zydus Life arm plea
* Earnings Review: Max Health Q1 PAT up on healthy sales growth but misses view
* Earnings Review: IPCA Lab Apr-Jun PAT up 72% YoY, beats Street view by 30%
* Earnings Review: Abbott India Q1 PAT up 17% YoY; sales up 4% YoY
* Caplin Point Apr-Jun consol PAT rises 15.8% YoY to INR 1.77 billion
* Marksans Pharma Apr-Jun consol PAT up nearly 3-fold YoY at INR 1.57 billion
* Glenmark Pharma US arm settles dispute with Humana for $15.28 million
* Analyst Concall: Zydus Life sees FY28 US growth better on portfolio scale-up
* Zydus Life's US arm, Mereo BioPharma ink pact to manufacture, sell alvelestat
* Semaglutide generic launches drive GLP-1 volume growth, temper value growth
* HC asks Sun Pharma arm to seek court nod before launching semaglutide tablet
* Earnings Review: Viyash Scientific Q1 PAT more than doubles, sales rise 19%
* Earnings Review: Zydus Life Q1 PAT misses view, falls 36% on yr on high base
* Analyst Concall: Gland Pharma says CDMO ops remain key pillar to drive growth
* Lupin gets US FDA approval for sodium zirconium cyclosilicate
* Jubilant Pharmova Apr-Jun consol PAT falls 45.1% YoY to INR 565 million
* Earnings Review: CDMO, US sales lift Gland Pharma Q1 consol PAT, revenue YoY
* Zydus Life launches REVAHALE for chronic obstructive pulmonary disease
* Wockhardt posts INR-1.06-billion consol PAT in Apr-Jun vs loss year ago
* AstraZeneca Apr-Jun PAT falls 32.1% YoY to INR 379.3 million
* Gland Pharma to sell injectables to global co, sees up to $100 mln/yr sales
* Akums Drugs Apr-Jun PAT falls 0.1% YoY to INR 448.39 million
* Pharmatrac: Semaglutide mkt sees strong Jul pickup after brief lull May-Jun
* US FDA classifies Emcure Pharma Sanand unit as 'voluntary action indicated'
* Dr Reddy's ends distribution, promotion agreement with Novartis India
* Analyst Concall: Lupin expects sharp growth moderation in US in coming qtrs
* Pharma Secy sets fresh 3-4 month timeline for Biopharma SHAKTI Cabinet nod

 

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

 

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	27,060.00	(-)2.80	28,086.70	26,486.70
Alkem Laboratories	5,368.00	(-)4.50	5,603.30	5057.30
Aurobindo Pharma	1,622.10	(-)2.20	1,686.10	1,589.90
Biocon	417.00	(-)2.20	424.60	409.30
Cipla	1,450.00	(-)0.90	1,482.90	1,432.70
Divi's Laboratories	8,477.00	2.40	8,614.70	8,396.70
Dr Reddy's Laboratories	1,200.00	2.40	1,212.90	1,185.90
Gland Pharma	2,970.20	14.20	3,078.70	2,892.30
GlaxoSmithKline Pharmaceuticals	2,688.80	3.40	2,726.90	2,628.90
Glenmark Pharmaceuticals	2,318.40	1.70	2,356.80	2,288.00
Granules India	858.40	(-)1.80	869.60	848.40
Ipca Laboratories	1,734.20	(-)0.10	1,838.10	1,668.10
Laurus Labs	1,787.30	(-)3.10	1,881.60	1,730.60
Lupin	2,235.00	(-)5.40	2,275.70	2,209.70
Natco Pharma	903.15	(-)1.50	996.60	839.60
Pfizer	4,874.80	(-)0.10	5,096.90	4,752.90
Sanofi India	3,242.90	(-)3.20	3,323.00	3,191.00
Sun Pharmaceutical Industries	1,930.00	(-)0.80	1,949.50	1,904.90
Torrent Pharmaceuticals	4,833.00	(-)1.90	4,943.00	4,778.00
Zydus Lifesciences	1,135.20	1.90	1,186.00	1,109.80
Index	Levels
Nifty Pharma	26445.55	(-)0.40	26838.20	26197.60
Nifty 50	24366.00	(-)0.80	24464.40	24247.60
S&P Bse Sensex	78009.25	(-)0.60	78278.70	77549.60

 

End

 

Reported by Eshitva Prakash

Edited by Shubhayan Bhattacharya

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.